Vitamin D and glucose metabolism in chronic kidney disease

Current Opinion in Nephrology and Hypertension

Volumn 17, Issue 6, 2008, Pages 566-572

  De Boer, Ian H ^a,b  

^a UNIVERSITY OF WASHINGTON SCHOOL OF MEDICINE   (United States)

^b NONE   (United States)

Author keywords

Chronic kidney disease; Glucose intolerance; Insulin resistance; Vitamin D

Indexed keywords

CALCITRIOL; CALCIUM; COLECALCIFEROL; ERGOCALCIFEROL; GLUCOSE; HEMOGLOBIN A1C; INSULIN; MEGALIN; OXYGENASE; VITAMIN D;

CALCIUM INTAKE; CARDIOVASCULAR DISEASE; CHRONIC KIDNEY DISEASE; CLINICAL TRIAL; DIABETES MELLITUS; DRUG EFFECT; GLUCOSE CLAMP TECHNIQUE; GLUCOSE METABOLISM; GLUCOSE TOLERANCE; HEMODIALYSIS; HUMAN; INSULIN RELEASE; INSULIN SENSITIVITY; INTRAVENOUS GLUCOSE TOLERANCE TEST; MORTALITY; OBESITY; PLEIOTROPY; POSTMENOPAUSE; PRIORITY JOURNAL; REVIEW; SINGLE DRUG DOSE; TREATMENT DURATION; VITAMIN D DEFICIENCY; VITAMIN D METABOLISM; VITAMIN SUPPLEMENTATION;

ANIMALS; CHRONIC DISEASE; GLUCOSE; GLUCOSE INTOLERANCE; HUMANS; KIDNEY DISEASES; TREATMENT OUTCOME; VITAMIN D; VITAMIN D DEFICIENCY;

EID: 56249137611     PISSN: 10624821     EISSN: None     Source Type: Journal    
DOI: 10.1097/MNH.0b013e32830fe377     Document Type: Review

References (68)

1. Standing Committee on the Scientific Evaluation of Dietary Reference Intakes FaNB, Institute of Medicine. Dietary reference intakes for calcium, phosphorous, magnesium, vitamin D, and fluoride. Washington, DC: National Academy Press; 1997.
2. Christensen EI, Bim H. Megalin and cubilin: synergistic endocytic receptors in renal proximal tubule. Am J Physiol Renal Physiol 2001; 280;F562-F573.
3. Levin A, Bakris GL, Molitch M, et al. Prevalence of abnormal serum vitamin D, PTH, calcium, and phosphorus in patients with chronic kidney disease: results of the study to evaluate early kidney disease. Kidney Int 2007; 71:31-38.
4. Andress DL. Vitamin D treatment in chronic kidney disease. Semin Dial 2005; 18:315-321.
5. 2 were found to be independent risk factors for insulin resistance in the US population.
6. Wolf M, Shah A, Gutierrez O, et al. Vitamin D levels and early mortality among incident hemodialysis patients. Kidney Int 2007; 72:1004-1013. Among incident hemodialysis patients, low 25-OHD concentrations, and low calcitriol concentrations to a lesser extent, were associated with increased risk for all-cause mortality within 3 months. This risk was abrogated by vitamin D therapy (nonrandomized intervention).
7. Schmidt-Gayk H, Grawunder C, Tschope W, et al. 25-hydroxy-vitamin-D in nephrotic syndrome. Lancet 1977; 2:105-108.
8. Wortsman J, MatsuokaLY, Chen TC, et al. Decreased bioavailability of vitamin D in obesity. Am J Clin Nutr 2000; 72:690-693.
9. Sato KA, Gray RW, Lemann J Jr. Urinary excretion of 25-hydroxyvitamin D in health and the nephrotic syndrome. J Lab Clin Med 1982; 99:325-330.
10. Portale AA, Booth BE, Halloran BP, Morris RC Jr. Effect of dietary phosphorus on circulating concentrations of 1,25-dihydroxyvitamin D and immunoreactive parathyroid hormone in children with moderate renal insufficiency. J Clin Invest 1984; 73:1580-1589.
11. Vanholder R, Patel S, Hsu CH. Effect of uric acid on plasma levels of 1,25(OH)2D in renal failure. J Am Soc Nephrol 1993; 4:1035-1038.
12. Kawashima H, Kraut JA, Kurokawa K. Metabolic acidosis suppresses 25-hydroxyvitamin in D3-1alpha-hydroxylase in the rat kidney. Distinct site and mechanism of action. J Clin Invest 1982; 70:135-140.
13. Gutierrez O, Isakova T, Rhee E, et al. Fibroblast growth factor-23 mitigates hyperphosphatemia but accentuates calcitriol deficiency in chronic kidney disease. J Am Soc Nephrol 2005; 16:2205-2215.
14. Liu S, Quarles LD. How fibroblast growth factor 23 works. J Am Soc Nephrol 2007; 18:1637-1647.
15. US Renal Data System. USRDS 2005 annual data report: atlas of end-stage renal disease in the United States. Bethesda, MD: National Institutes of Health, National Institute of Diabetes and Digestive and Kidney Diseases; 2005.
16. Go AS, Chertow GM, Fan D, et al. Chronic kidney disease and the risks of death, cardiovascular events, and hospitalization. N Engl J Med 2004; 351:1296-1305.
17. Wang TJ, Pencina MJ, Booth SL, et al. Vitamin D deficiency and risk of cardiovascular disease. Circulation 2008; 117:503-511. Low 25-OHD concentrations were associated with increased risk of cardiovascular events over long-term follow-up in the Framingham Offspring cohort.
18. Teng M, Wolf M, Ofsthun MN, et al. Activated injectable vitamin D and hemodialysis survival: a historical cohort study. J Am Soc Nephrol 2005; 16:1115-1125.
19. Tentori F, Hunt WC, Stidley CA, et al. Mortality risk among hemodialysis patients receiving different vitamin D analogs. Kidney Int 2006; 70:1858-1865.
20. Melamed ML, Eustace JA, Plantinga L, et al. Changes in serum calcium, phosphate, and PTH and the risk of death in incident dialysis patients: a longitudinal study. Kidney Int 2006; 70:351-357.
21. Shoben AB, Rudser KD, de Boer IH, et al. Association of oral calcitriol with improved survival in nondialyzed CKD. J Am Soc Nephrol 2008 [Epub ahead of print]. Oral calcitriol therapy was associated with a 26% reduction in all-cause mortality in this well designed cohort study of stages 3 and 4 CKD.
22. Kovesdy CP, Ahmadzadeh S, Anderson JE, Kalantar-Zadeh K. Association of activated vitamin D treatment and mortality in chronic kidney disease. Arch Intern Med 2008; 168:397-403. Oral calcitriol therapy was associated with a 65% reduction in predialysis mortality in stages 3-5 CKD.
23. Coen G, Mazzaferro S, Manni M, et al. No acceleration and possibly slower progression of renal failure during calcitriol treatment in predialysis chronic renal failure. Nephrol Dial Transplant 1994; 9:1520.
24. Dusso AS, Brown AJ, Slatopolsky E. Vitamin D. Am J Physiol Renal Physiol 2005; 289:F8-F28.
25. Li YC, Kong J, Wei M, et al. 1,25-Dihydroxyvitamin D(3) is a negative endocrine regulator of the renin-angiotensin system. J Clin Invest 2002; 110:229-238.
26. Lind L, Lithell H, Skarfors E, et al. Reduction of blood pressure by treatment with alphacalcidol. A double-blind, placebo-controlled study in subjects with impaired glucose tolerance. Acta Med Scand 1988; 223:211-217.
27. Li YC, Qiao G, Uskokovic M, et al. Vitamin D: a negative endocrine regulator of the renin-angiotensin system and blood pressure. J Steroid Biochem Mol Biol 2004; 89-90:387-392.
28. Kuhlmann A, Haas CS, Gross ML, et al. 1,25-Dihydroxyvitamin D3 decreases podocyte loss and podocyte hypertrophy in the subtotally nephrectomized rat. Am J Physiol Renal Physiol 2004; 286:F526-F533.
29. de Boer IH, Ioannou GN, Kestenbaum B, et al. 25-Hydroxyvitamin D levels and albuminuria in the Third National Health and Nutrition Examination Survey (NHANES III). Am J Kidney Dis 2007; 50:69-77.
30. Agarwal R, Acharya M, Tian J, et al. Antiproteinuric effect of oral paricalcitol in chronic kidney disease. Kidney Int 2005; 68:2823-2828.
31. American Diabetes Association. Standards of medical care in diabetes: 2007. Diabetes Care 2007; 30 (Suppl 1):S4-S41.
32. Ferrannini E, Mari A. How to measure insulin sensitivity. J Hypertens 1998; 16:895-906.
33. Matthews DR, Hosker JP, Rudenski AS, et al. Homeostasis model assessment: insulin resistance and beta-cell function from fasting plasma glucose and insulin concentrations in man. Diabetologia 1985; 28:412-419.
34. DeFronzo RA, Tobin JD, Rowe JW, Andres R. Glucose intolerance in uremia. Quantification of pancreatic beta cell sensitivity to glucose and tissue sensitivity to insulin. J Clin Invest 1978; 62:425-435.
35. Bergman RN, Ider YZ, Bowden CR, Cobelli C. Quantitative estimation of insulin sensitivity. Am J Physiol 1979; 236:E667-E677.
36. Siew ED, Ikizler TA. Determinants of insulin resistance and its effects on protein metabolism in patients with advanced chronic kidney disease. Contrib Nephrol 2008; 161:138-144.
37. DeFronzo RA, Alvestrand A, Smith D, et al. Insulin resistance in uremia. J Clin Invest 1981; 67:563-568.
38. Allegra V, Mengozzi G, Martimbianco L, Vasile A. Glucose-induced insulin secretion in uremia: effects of aminophylline infusion and glucose loads. Kidney Int 1990; 38:1146-1150.
39. Chen J, Muntner P, Hamm LL, et al. Insulin resistance and risk of chronic kidney disease in nondiabetic US adults. J Am See Nephrol 2003; 14:469-477.
40. Menon V, Greene T, Pereira AA, et al. Glycosylated hemoglobin and mortality in patients with nondiabetic chronic kidney disease. J Am Soc Nephrol 2005; 16:3411-3417.
41. Lin-Tan DT, Lin JL, Wang LH, et al. Fasting glucose levels in predicting 1-year all-cause mortality in patients who do not have diabetes and are on maintenance hemodialysis. J Am Soc Nephrol 2007; 18:2385-2391.
42. Oomichi T, Emoto M, Tabata T, et al. Impact of glycemic control on survival of diabetic patients on chronic regular hemodialysis: a 7-year observational study. Diabetes Care 2006; 29:1496-1500.
43. Kalantar-Zadeh K, Kopple JD, Regidor DL, et al. A1C and survival in maintenance hemodialysis patients. Diabetes Care 2007; 30:1049-1055.
44. Hayashino Y, Fukuhara S, Akiba T, et al. Diabetes, glycaemic control and mortality risk in patients on haemodialysis: the Japan Dialysis Outcomes and Practice Pattern Study. Diabetologia 2007; 50:1170-1177.
45. Williams ME, Lacson E Jr, Teng M, et al. Hemodialyzed type I and type II diabetic patients in the US: characteristics, glycemic control, and survival. Kidney Int 2006; 70:1503-1509.
46. Norman AW, Frankel JB, Heldt AM, Grodsky GM. Vitamin D deficiency inhibits pancreatic secretion of insulin. Science 1980; 209:823-825.
47. Sergeev IN, Rhoten WB. 1,25-Dihydroxyvitamin D3 evokes oscillations of intracellular calcium in a pancreatic beta-cell line. Endocrinology 1995; 136:2852-2861.
48. Maestro B, Campion J, Davila N, Calle C. Stimulation by 1,25-dihydroxyvitamin D3 of insulin receptor expression and insulin responsiveness for glucose transport in U-937 human promonocytic cells. Endocr J 2000; 47:383-391.
49. Maestro B, Davila N, Carranza MC, Calle C. Identification of a vitamin D response element in the human insulin receptor gene promoter. J Steroid Biochem Mol Biol 2003; 84:223-230.
50. Maestro B, Molero S, Bajo S, et al. Transcriptional activation of the human insulin receptor gene by 1,25-dihydroxyvitamin D(3). Cell Biochem Funct 2002; 20:227-232.
51. Baynes KC, Boucher BJ, Feskens EJ, Kromhout D. Vitamin D, glucose tolerance and insulinaemia in elderly men. Diabetologia 1997; 40:344-347.
52. Chiu KC, Chu A, Go VL, Saad MF. Hypovitaminosis D is associated with insulin resistance and beta cell dysfunction. Am J Clin Nutr 2004; 79:820-825.
53. Ford ES, Ajani UA, McGuire LC, Liu S. Concentrations of serum vitamin D and the metabolic syndrome among U.S. adults. Diabetes Care 2005; 28:1228-1230.
54. Scragg R, Sowers M, Bell C. Serum 25-hydroxyvitamin D, diabetes, and ethnicity in the Third National Health and Nutrition Examination Survey. Diabetes Care 2004; 27:2813-2818.
55. Quesada JM, Martin-Malo A, Santiago J, et al. Effect of calcitriol on insulin secretion in uraemia. Nephrol Dial Transplant 1990; 5:1013-1017.
56. Mak RH. Intravenous 1,25 dihydroxycholecalciferol corrects glucose intolerance in hemodialysis patients. Kidney Int 1992; 41:1049-1054.
57. Mak RH. Amelioration of hypertension and insulin resistance by 1,25-dihydroxycholecalciferol in hemodialysis patients. Pediatr Nephrol 1992; 6: 345-348.
58. Allegra V, Luisetto G, Mengozzi G, et al. Glucose-induced insulin secretion in uremia: role of 1 alpha,25(HO)2-vitamin D3. Nephron 1994; 68:41-47.
59. Lin SH, Lin YF, Lu KC, et al. Effects of intravenous calcitriol on lipid profiles and glucose tolerance in uraemic patients with secondary hyperparathyroidism. Clin Sci (Lond) 1994; 87:533-538.
60. Kautzky-Willer A, Pacini G, Bamas U, et al. Intravenous calcitriol normalizes insulin sensitivity in uremic patients. Kidney Int 1995; 47:200-206.
61. Mak RH. 1,25-Dihydroxyvitamin D3 corrects insulin and lipid abnormalities in uremia. Kidney Int 1998; 53:1353-1357.
62. Khajehdehi P, Taheri S. Effect of oral calcitriol pulse therapy on the lipid, calcium, and glucose homeostasis of hemodialysis-patients: its safety in a combination with oral calcium carbonate. J Ren Nutr 2003; 13:78-83.
63. Strozecki P, Kretowicz M, Odrowaz-Sypniewska G, Manitius J. The influence of intravenous 1,25(OH)2D3 therapy on glucose metabolism in hemodialyzed patients with secondary hyperparathyroidism. Ren Fail 2004; 26:345-348.
64. Pittas AG, Lau J, Hu FB, Dawson-Hughes B. The role of vitamin D and calcium in type 2 diabetes. A systematic review and meta-analysis. J Clin Endocrinol Metab 2007; 92:2017-2029.
65. Autier P, Gandini S. Vitamin D supplementation and total mortality: a meta-analysis of randomized controlled trials. Arch Intern Med 2007; 167:1730-1737. Cholecalciferol or ergocalciferol supplementation decreased all-cause mortality by a statistically significant 7% in this large meta-analysis from the general population.
66. Pittas AG, Harris SS, Stark PC, Dawson-Hughes B. The effects of calcium and vitamin D supplementation on blood glucose and markers of inflammation in nondiabetic adults. Diabetes Care 2007; 30:980-986.
67. de Boer IH, Tinker LF, Connelly S, et al. Calcium plus vitamin D supplementation and the risk of incident diabetes in the Women's Hearth Initiative. Diabetes Care 2008; 31:701-707. Cholecalciferol and calcium supplementation did not affect the risk of incident drug-treated diabetes among postmenopausal women in the largest clinical trial of vitamin D to date.
68. de Boer IH, Kestenbaum B. Vitamin D in chronic kidney disease: is the jury in? Kidney Int (in press).